Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens
Authors:
- Alexander K. AndrianovAlexander K. Andrianov
- Alexander MarinAMAlexander Marin
- Sarah JeongSJSarah Jeong
- Liudmila KulakovaLKLiudmila Kulakova
- Ananda ChowdhuryACAnanda Chowdhury
- Raman HlushkoRHRaman Hlushko
- Sayan DasSDSayan Das
- Francesca MoyFMFrancesca Moy
- Eric A. TothETEric A. Toth
- Robert K. ErnstRERobert K. Ernst
- Thomas R. FuerstTFThomas R. Fuerst
Open Access
- 28 September 2025
- Vol. 13 (10) , 1012
Abstract
Background: The quest for well-defined immunoadjuvants remains one of the highest priorities for the successful development of effective vaccines. Combination adjuvants, which are designed to integrate both the ability to activate a variety of immune mechanisms and synergistically improve the delivery of vaccine components, are well-positioned to address the unmet needs. The development of a preventive vaccine against hepatitis C virus (HCV)—a major public health concern—is a particular instance in which the choice of the immunoadjuvant is of utmost importance. Methods: We assembled a lipid A Toll-like receptor 4 (TLR4) agonist BECC438 and TLR7/8 agonist resiquimod (R848) on a polyphosphazene macromolecule (PCPP) to create a nanoscale immunoadjuvant-vaccine delivery system: PCPP-R+BECC438. This aqueous-based system was formulated with the HCV sE2 antigen, and the resulting vaccine candidate was evaluated in vivo for the ability to induce immune responses. Results: Co-assembly of adjuvants resulted in a visually clear aqueous system of nanoscale dimensions, monomodal size distribution, and entropy-driven interactions between components. Intramuscular immunization of mice with HCV sE2 antigen formulated in a polyphosphazene-based nano-system induced ten-fold higher IgG and IgG2a titers than the antigen adjuvanted with BECC438 alone. PCPP-R+BECC438 formulated HCV sE2 also produced statistically significant improvements in IgG2a/IgG1 ratio and more robust HCVpp neutralization ID50 titers than control formulations. Conclusions: Polyphosphazene-assembled adjuvant nano-system promotes in vivo immune responses of enhanced quantity and quality of antibodies with increased potency of HCV neutralization.Keywords
All Related Versions
Funding Information
- National Institutes of Health (R01 AI132212, R01 AI168048, HHS-NIH-NIAID-BAA2017)
This publication has 47 references indexed in Scilit:
- Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antiviralsCurrent Opinion in Virology, 2024
- Polyphosphazene immunoadjuvants: Historical perspective and recent advancesJournal of Controlled Release, 2021
- Hepatitis C virus recurrence in two patients who achieved sustained viral response with interferon-free direct-acting antiviral therapy: reinfection or relapse?Clinical Journal of Gastroenterology, 2019
- Lipids and polymers in pharmaceutical technology: Lifelong companionsInternational Journal of Pharmaceutics, 2019
- Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohortJournal of Hepatology, 2018
- Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsDrug Safety, 2015
- The effect of stable macromolecular complexes of ionic polyphosphazene on HIV Gag antigen and on activation of human dendritic cells and presentation to T-cellsBiomaterials, 2014
- Vaccine adjuvant formulations: A pharmaceutical perspectiveSeminars in Immunology, 2013
- Activation of adjuvant core response genes by the novel adjuvant PCEPMolecular Immunology, 2012
- Nanosizing — Oral formulation development and biopharmaceutical evaluationAdvanced Drug Delivery Reviews, 2007